
Overview
Canpoland is the first Polish pharmaceutical company engaged in the international trade of medical marijuana and is establishing a production facility for it in Poland. The company also provides repackaging services and wholesale distribution of pharmaceuticals, holding licenses for the trade of medical marijuana in Poland. Additionally, Canpoland distributes unique and rare medications and offers training for pharmacists on the products they distribute.
Financials
Revenue history (in k)
Financial insight
- The statement flags a going concern risk. W dniu 10 listopada 2023 roku Sąd Rejonowy dla Łodzi- Śródmieścia w Łodzi swym postanowieniem zatwierdził układ z wierzycielami i począwszy od maja 2024 roku, Spółka realizuję plan restrukturyzacyjny. Sprawozdanie finansowe zostało sporządzone przy założeniu kontynuacji działalności, niemniej Spółka w obecnej sytuacji finansowej wymaga dalszego dokapitalizowania ze strony akcjonariuszy i inwestorów, aby zrealizować założone cele.
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 87 days late). All were audited by a statutory auditor.
- 202503/07/2026
- 202415/07/2025
- 202308/07/2024
- 202213/07/2023
- 202110/10/2022
- 202007/10/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

Notice of Convening the Extraordinary General Meeting of Shareholders on 26.06.2026

Supplementary invitation to submit offers to acquire shares of CANPOLAND S.A.

Invitation to submit offers to acquire shares of CANPOLAND S.A.

Notice to shareholders of CanPoland S.A.

Renewed invitation to submit offers to acquire the entire package of rights from CanPoland S.A. shares

Notice: Extension of the deadline for submitting offers
Industry
Trademarks
The company holds 1 active trademark registered with the Polish Patent Office. The first mark was filed in 2020.
| Mark | Protected until | |
|---|---|---|
| CANPOLAND | Jan 20, 2030 |
Authorized Representatives
Manner of representation
The company is represented by the management board as follows: a) in the case of a one-person management board, the company is represented by one member of the management board; b) in the case of a management board consisting of more than one person: (i) if no Vice-President of the Management Board is appointed, performing legal acts and submitting declarations on behalf of the company requires the President of the Management Board to act independently or the joint action of two members of the management board, one of whom must always be the President of the Management Board; (ii) if a Vice-President of the Management Board is appointed, each member of the management board acting independently is authorised to incur obligations and make dispositions with a value not exceeding PLN 100,000.00 (one hundred thousand złoty). In the case of continuing obligations, the value of the obligation for a period of 12 months is taken into account. In other cases, the Vice-President must act independently or two members of the management board must act jointly, one of whom must always be the Vice-President of the Management Board.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
THE Health Company Poland sp. z o.o. | 1,350.62 USD | 50% |
Bank accounts
Was a VAT taxpayer from 2023-06-01 to 2026-05-27.
Reason for removal: Art. 96 ust. 9 pkt 4 (taxpayer or their representative fails to appear on summons of tax authorities)
Debt
2 closed proceedings recorded in KRZ history.
| Registration date | Proceeding type | Status | |
|---|---|---|---|
| Apr 3, 2023 | Proceedings after filing an arrangement approval application | Closed | |
| Dec 2, 2022 | Arrangement approval proceedings | Closed |
MSiG notices
7 notices recorded in the Court and Commercial Gazette (MSiG).
| Publication date | Event | |
|---|---|---|
| Jun 9, 2026 | Shareholders' meeting convened | |
| Jun 6, 2025 | Shareholders' meeting convened | |
| Jun 5, 2024 | Shareholders' meeting convened | |
| Sep 7, 2022 | Shareholders' meeting convened | |
| Feb 10, 2021 | Commercial Companies Code notice |
Public aid
10 public aid cases recorded, with a total value of $32,708.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jan 9, 2026 | Aid for microenterprises in the form of public interventions concerning electricity, gas or heat supplies | $114$114 | PGE Obrót S.A. | |
| Jun 6, 2024 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $936$936 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Apr 11, 2023 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $702$702 | Prezes Zakładu Ubezpieczeń Społecznych |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Canopy Growth Polska sp. z o.o. | $1,371,799.08 | spectrumtherapeutics.pl | ||
| Solinea Pharma sp. z o.o. | $1,000,645.63 | solinea.pl | ||
| Sincofarm sp. z o.o. | $407,150.59 | sincofarm.pl | ||
| Bonopharm sp. z o.o. | $405,123.74 | bonopharm.com | ||
| MEDI Select sp. z o.o. | $311,634.51 | mediselect.pl | ||
| Sanata Group sp. z o.o. | $201,180.63 | sanata.pl | ||
| Biocanto Pharma sp. z o.o. | $186,097.96 | biocanto.pl | ||
| Pharmatonica sp. z o.o. | $172,500.36 | pharmatonica.pl | ||
| Toto Pharma Poland sp. z o.o. | $66,269.14 | totopharma.com | ||
| THC Pharma S.A. | $39,093.70 | thc-pharma.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-12-05 | Address change (Ul. Beskidzka 190, 91-610, Łódź → Ul. Polskiej Organizacji Wojskowej 29/1, 90-248, Łódź) | |
| 2022-02-18 | Share capital increase (274,725.00 PLN → 292,125.00 PLN) | |
| 2021-06-07 | Share capital increase (257,125.00 PLN → 274,725.00 PLN) | |
| 2020-12-18 | Share capital increase (225,100.00 PLN → 257,125.00 PLN) | |
| 2020-11-04 | Share capital increase (200,100.00 PLN → 225,100.00 PLN) |
FAQ
Last updated: 2026-07-06